EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括主席兼執行董事涂志亮先生，非執行董事HUANG Jingsheng先生及劉康華先生，獨立非執行董事王蘭 女士、李鐵先生及仲偉合先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 固生堂控股有限公司 | | 股份代號 | 02273 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 宣派及支付截至2025年6月30日止六個月中期股息及暫停辦理股份過戶登記 | | | 公告日期 | 2025年8月29日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 （根據開曼群島法律註冊成立的有限公司） （股份代號：2273） 中期業績公告 截至2025年6月30日止六個月 財務摘要 本集團的收入由截至2024年6月30日止六個月的人民幣1,365.0百萬元增加9.5% 至截至2025年6月30日止六個月的人民幣1,494.9百萬元。 董事會欣然公佈本集團截至2025年6月30日止六個月的未經審核綜合中期業績， 連同於2024年同期的比較數字載列如下。 未經審核中期簡明綜合損益及其他全面收益表 截至2025年6月30日止六個月 | | 附註 | 2025年 | 2024年 | | --- | --- | --- | --- | | | | 人民幣千元 | 人民幣千元 | | | | （未經審核）（未經審核） | | | 收入 | 4 | 1,494,891 | 1,364 ...

格隆汇8月19日丨固生堂(02273.HK)公告，董事会会议将于2025年8月29日(星期五)举行，藉以(其中包 括)考虑及批准集团截至2025年6月30日止6个月未经审核中期业绩及其刊发，并考虑派发中期股息(如 有)。 ...

香港交易所及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 （股份代號：2273） 董事會會議日期 固生堂控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱為「本 集團」）董事（「董事」）會（「董事會」）謹此宣佈，董事會會議將於二零二五年八 月二十九日（星期五）舉行，藉以（其中包括）考慮及批准本集團截至二零二五 年六月三十日止六個月之未經審核中期業績及其刊發，並考慮派發中期股息（如 有）。 承董事會命 GUSHENGTANG HOLDINGS LIMITED 固生堂控股有限公司 董事會主席 涂志亮 香港，二零二五年八月十九日 於本公告日期，本公司董事會包括主席兼執行董事涂志亮先生，非執行董事HUANG Jingsheng 先生及劉康華先生，獨立非執行董事王蘭女士、李鐵先生及仲偉合先生。 （根據開曼群島法律註冊成立的有限公司） ...

8月15日，智能创新驱动的中医药高质量发展大会在广州举办。会上，固生堂(02273)中医集团副总裁林 小燕以《领航中医国际化-让中医成为世界主流医疗》为题，系统阐述了公司以"管理赋能+AI技术+产 品"三驾马车推动中医药国际化的战略布局，致力于打造全球华人中医医疗健康第一品牌。 一、管理出海：成熟模式赋能，"自建+并购"构建海外版图 2024年3月，固生堂收购新加坡宝中堂，正式开启国际化的新征程。通过复制国内成熟的运营模式，新 加坡宝中堂在短短一年内实现业绩飞跃：2025年7月收入同比增长119%，专家首诊回头率和现场预约率 均位居集团前列。 "新加坡市场的成功验证了我们的国际化模式"，固生堂副总裁林小燕表示，"我们将持续加大投入，预 计到2026年底在新加坡拓展至30家诊所规模"。 经过10余年的深耕，固生堂已形成一套成熟的市场拓展方法论。在海外市场，公司将采取"自建+并购 +合作"多模式并举策略拓展业务规模：一是自建旗舰店，快速提升在消费者心中的品牌认知。二是战 略合作与整合，公司计划与新加坡当地连锁中医机构合作，实现整体业绩的增长。三是并购及相互持 股，一方面，与当地连锁西医诊所合作开店，互相持股；另一 ...

Core Viewpoint - The conference on high-quality development of traditional Chinese medicine (TCM) highlighted the strategic layout of Guoshengtang in promoting the internationalization of TCM through "management empowerment + AI technology + products" to establish itself as the leading TCM health brand for the global Chinese community [1] Group 1: Management Strategy - Guoshengtang has initiated its internationalization journey by acquiring Singapore's Baozhongtang, achieving a revenue increase of 119% year-on-year by July 2025 [1] - The company plans to expand to 30 clinics in Singapore by the end of 2026, leveraging its successful operational model from China [1] - The company employs a multi-faceted strategy for overseas expansion, including self-built flagship stores, strategic partnerships, and acquisitions of local medical institutions [2] Group 2: AI Technology - Guoshengtang launched 10 AI avatars of renowned TCM doctors to address the shortage of quality TCM talent overseas, enhancing the internationalization of TCM [2][3] - The AI avatars have achieved over 86% consistency with expert simulations, improving diagnostic accuracy and medication rationality [4] - The AI technology aids in alleviating the scarcity of quality TCM resources and enhances the efficiency of top experts, while also supporting the training of younger doctors [4] Group 3: Product Development - Guoshengtang has made significant advancements in the development of traditional Chinese medicine (TCM) products, with its first proprietary TCM product receiving certification in Singapore [5][6] - The company has initiated a project to create an integrated platform for clinical evaluation of TCM, leveraging AI and big data to enhance clinical research and innovation [6] - Guoshengtang aims to strengthen its product development efforts, focusing on innovative TCM formulations and ensuring the legacy of renowned TCM practitioners through its products [7]

Core Insights - The conference on high-quality development of traditional Chinese medicine (TCM) and the launch of the Guoshengtang National Medicine AI system took place in Guangzhou, highlighting significant collaborations and achievements by Guoshengtang [1] Group 1: Partnerships and Collaborations - Guoshengtang signed medical alliance agreements with Shenzhen Baoan District Traditional Chinese Medicine Hospital and Guangzhou University of Traditional Chinese Medicine Shenzhen Hospital, marking a milestone in expanding quality TCM services [3] - The company acquired a secondary specialized hospital in Shenzhen, enhancing its offline and online medical service capabilities [3] - Collaborations with various partners, including Xiaohongshu and Guotu Innovation, aim to integrate resources, improve patient services, and provide technical support [1][3] Group 2: Service Enhancement - Guoshengtang's partnership with Xiaohongshu represents a significant step in digitalizing TCM services, allowing for a more extensive reach to both domestic and international audiences [6][8] - The collaboration will enable Guoshengtang to utilize Xiaohongshu's content ecosystem for better customer engagement through various formats like notes and live broadcasts [8][9] Group 3: Technological Innovation - The launch of 10 National Medicine AI avatars aims to accelerate the internationalization of TCM by enhancing diagnostic capabilities and ensuring consistency with expert decision-making [10][12] - The AI avatars are designed to improve the productivity of experts significantly, allowing for more efficient online consultations [12] - Guoshengtang is also establishing a TCM inheritance studio in Singapore to train overseas practitioners, thereby addressing the talent gap in international TCM services [12][13] Group 4: Strategic Vision - Guoshengtang aims to combine traditional TCM with modern technology and AI, positioning itself as a leading TCM brand for the global Chinese community [13][14] - The company's mission is to facilitate the global reach of TCM, leveraging technology to enhance its traditional practices [14]

8月15日，"智能创新驱动的中医药高质量发展暨固生堂国医AI系统发布会"在广州举办。会上，固生堂 与小红书达成商业化深度合作 —— 这一标志性事件不仅让固生堂成为全国首家与小红书达成官方合作 的中医医疗机构，更标志着固生堂的流量生态布局完成从单一品牌流量向平台型矩阵式流量的关键转 型，为中医药服务的数字化传播与普及注入新动能。 一、小红书深度合作落地，开启中医流量运营新场景 三、聚焦流量入口能力建设，夯实中医服务运营优势 事实上，聚焦流量入口能力的建设并非偶然，而是固生堂战略布局的重要一步。今年6月，固生堂创始 人、董事长涂志亮提出科技型中医集团转型目标，明确 "流量入口能力" 为四大核心能力之一，计划通 过强化与美团、小红书、抖音等热门平台的合作，打通平台生态实现高效获客。 在这一战略指引下，固生堂在流量运营上已形成显著优势，获客成本低于行业平均水平，用户复诊率与 品牌信任度持续提升。以2025年7月为例，固生堂全集团流量获客订单数逾4万单，环比2025年6月增长 1.3万单，环比提升40%；较24年同比增加近2万单，同比增长75%。其中，美团平台7月份获客订单数逾 3万单，环比增长35%。由此可见，固生堂 ...

Core Insights - The article highlights the top short-selling stocks in the market, focusing on their short-selling ratios, amounts, and deviation values [1][2][3] Short-Selling Ratios - The top three stocks by short-selling ratio are: - China Resources Beer-R (80291) at 100.00% - Bank of China Hong Kong-R (82388) at 88.69% - Kuaishou-WR (81024) at 80.08% [1][2] Short-Selling Amounts - The leading stocks by short-selling amount are: - Alibaba-SW (09988) with a short-selling amount of 2.949 billion - Tencent Holdings (00700) with 2.711 billion - Meituan-W (03690) with 2.333 billion [1][3] Deviation Values - The stocks with the highest deviation values are: - China Resources Beer-R (80291) at 51.62% - Kuaishou-WR (81024) at 43.86% - Bank of China Hong Kong-R (82388) at 39.84% [1][2][3]

Group 1 - The core event was the launch of the "National Medicine AI Avatar" system by the company, aimed at enhancing the quality development of traditional Chinese medicine (TCM) and accelerating its international expansion [2][5] - The company has established partnerships with multiple hospitals in Shenzhen and internet platforms like Xiaohongshu, focusing on integrating medical resources and improving patient services [2][3] - The company has signed cooperative agreements with two new medical alliance units, enhancing the distribution of quality medical resources to grassroots levels and addressing public healthcare challenges [3] Group 2 - The company has expanded its medical alliance network to over 20 top TCM universities and hospitals, further broadening its national collaboration footprint [3] - The acquisition of Shenzhen Tianyuan Traditional Chinese Medicine Hospital aims to strengthen the synergy between offline stores and online medical platforms [3] - The company is committed to an integrated development model of "medical education research," focusing on building specialized TCM departments and a full-time physician training system [3][6] Group 3 - The "National Medicine AI Avatar" system covers eight core TCM specialties, leveraging the clinical experience of ten renowned TCM experts [5] - The AI system allows for efficient patient information collection and analysis, enabling quicker online consultations [6] - The company has established a TCM inheritance workshop in Singapore to enhance overseas TCM service capabilities and has developed 16 clinical formulations that have been approved for use [6] Group 4 - The company has formed partnerships with platforms like Meituan, Douyin, and Gaode Map, creating a multi-channel ecosystem for TCM service dissemination [4] - The collaboration with Xiaohongshu allows the company to utilize content formats like notes and live broadcasts to educate users about TCM [4]